Advertisement
Advertisement
VIVS
VivoSim Labs, Inc. Common Stock
0.36
USDSponsored
-0.10
-22.16%
Aug 10, 16:00 UTC -4
Closed
After-Market
0.36
0.00
-0.63%
VIVS Earnings Reports
Positive Surprise Ratio
VIVS beat 19 of 22 last estimates.
86%
Next Report
Today BMO
Date of Next Report
Aug 10, 2026
Estimate for Q1 26 (Revenue/ EPS)
$47.94K
/-$0.19
Implied change from Q4 25 (Revenue/ EPS)
+19.85%
/-91.40%
Implied change from Q1 25 (Revenue/ EPS)
+91.76%
/-93.12%
VivoSim Labs, Inc. Common Stock earnings per share and revenue
On Jul 14, 2026, VIVS reported earnings of -2.21 USD per share (EPS) for Q4 25, missing the estimate of -0.19 USD, resulting in a -1040.35% surprise. Revenue reached 40.00 thousand, compared to an expected 46.92 thousand, with a -14.75% difference. The market reacted with a -1.56% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of -0.19 USD, with revenue projected to reach 47.94 thousand USD, implying an decrease of -91.40% EPS, and increase of 19.85% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bionano Genomics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.69
Actual
-$0.64
Surprise
+8.40%
Biohaven Ltd.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.74
Actual
-$0.91
Surprise
-21.67%
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Rocket Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.24
Actual
-$0.15
Surprise
-160.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.38
Surprise
+4.95%
Nkarta, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.54
Surprise
-40.81%
FAQ
What were VivoSim Labs, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, VivoSim Labs, Inc. Common Stock reported EPS of -$2.21, missing estimates by -1040.35%, and revenue of $40.00K, -14.75% below expectations.
How did the market react to VivoSim Labs, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -1.56%, changed from $1.28 before the earnings release to $1.26 the day after.
When is VivoSim Labs, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for VivoSim Labs, Inc. Common Stock's next earnings report?
Based on 3
analysts, VivoSim Labs, Inc. Common Stock is expected to report EPS of -$0.19 and revenue of $47.94K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement